Literature DB >> 7475001

Role of leukocyte activation in patients with venous stasis ulcers.

P J Pappas1, S R Fallek, A Garcia, C T Araki, T L Back, W N Durán, R W Hobson.   

Abstract

Alteration in leukocyte activation has been implicated as an etiological factor in the development of chronic venous stasis ulcers (CVSU). The purpose of this study was to determine differences in expression of cell surface activation markers on circulating leukocytes and systemic, soluble, serum cytokine levels between healthy controls and patients with CVSU. Twenty-three patients were separated into two groups. Group I consisted of 12 healthy, adult, age-matched male patients with no venous disease. Group II consisted of 11 adult male patients with CVSU who underwent air plethysmography (APG) and duplex scanning to determine the severity of venous insufficiency. All patients had measurements of systemic, serum-based, soluble IL-1 beta, IL-2, IL-6, TNF-alpha, and beta 2 microglobulin levels. Using fluorescence flow cytometry, we measured the percentage of lymphocytes (CD3), monocytes (CD14), and granulocytes (CD15) expressing various cell surface activation markers. By APG and duplex scan, all group II patients exhibited venous insufficiency, with a mean venous filling index of 6.9 +/- 3.9 sec. Relative to group I, group II patients demonstrated a decreased expression of the CD3+/DR+ (13.3 +/- 1.5, P < or = 0.01) and CD3+/CD38+ (31.1 +/- 2.1, P < or = 0.04) markers on T-lymphocytes and an increased expression of CD14+/CD38+ (99.6 +/- 0.2, P < or = 0.008) markers on monocytes. Circulating neutrophils showed no evidence of activation. In addition, a significant elevation in the T-helper to T-suppressor ratio (2.9 +/- 0.6, P < or = 0.0001) between groups I and II was observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7475001     DOI: 10.1006/jsre.1995.1205

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  The treatment of venous ulcers of the lower extremities.

Authors:  Lonnie L Whiddon
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-10

2.  New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer.

Authors:  Hiroyuki Murota; Yorihisa Kotobuki; Noriko Umegaki; Mamori Tani; Ichiro Katayama
Journal:  Rheumatol Int       Date:  2008-05-07       Impact factor: 2.631

Review 3.  Immunological aspects of chronic venous disease pathogenesis.

Authors:  Ewa Grudzińska; Zenon Paweł Czuba
Journal:  Cent Eur J Immunol       Date:  2014-12-15       Impact factor: 2.085

4.  Immune mediators in patients with acute diabetic foot syndrome.

Authors:  Christian Weigelt; Bettina Rose; Ulrike Poschen; Dan Ziegler; Gerd Friese; Kerstin Kempf; Wolfgang Koenig; Stephan Martin; Christian Herder
Journal:  Diabetes Care       Date:  2009-06-09       Impact factor: 19.112

Review 5.  Latest Innovations in the Treatment of Venous Disease.

Authors:  Robert R Attaran
Journal:  J Clin Med       Date:  2018-04-11       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.